Imcyse develops disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors. Imcyse is backed by investors that include Belfius Bank, LSP BioVentures, Philippe Degive, SFPI-FPIM, and W.IN.G and is headquartered in Liege.
INDUSTRY:
Therapeutics
You are seconds away from signing up for the hottest list in New York Tech!
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.
